Grifols SA
grifols.comWhat Do They Do?
Sells medicines made from human plasma to healthcare providers for conditions including immune deficiencies and bleeding disorders. Also sells diagnostic products for clinical and blood-bank laboratories and products for hospitals.
20-F for FY2025, filed Apr 17, 2026We are one of the leading global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of…View ↗
Biopharma (formerly Bioscience). The Biopharma business unit includes activities relating to the manufacture of plasma derivatives for…View ↗
Diagnostic. The Diagnostic business unit focuses on researching, developing, manufacturing and marketing in vitro diagnostics products…View ↗
Other Activities and Operations. In addition to our four business units, we have other smaller operations, activities and business lines…View ↗
Who Are Their Customers?
Sells medicines, diagnostic products and hospital products to hospitals, clinics, specialty pharmacies, governments and distributors. In the United States, products reach customers through distributors, wholesalers and pharmacies as well as direct sales; diagnostic sales are direct, while sales in other regions use a mix of affiliates, distributors and direct channels.
20-F for FY2025, filed Apr 17, 2026We currently sell Biopharma, Diagnostic and Healthcare Solutions products to hospitals, specialty pharmacies, clinics, GPOs, governments…View ↗
For Biopharma and Healthcare Solutions in the United States, the sales model is complex, with many intermediaries, requiring us to execute…View ↗
For Diagnostics, the sales model consists of direct sales of Grifols solutions by a dedicated sales force primarily focusing on Integrated…View ↗
For Biopharma, the sales, marketing and distribution process is different in Europe, where the bulk of sales are generally made directly to…View ↗
For Diagnostics in Europe, the Middle East and Africa, sales and marketing is done through affiliates and distributors. The majority of the…View ↗
How Are They Changing?
Third-party plasma sales
Bio Supplies now includes plasma sales to third parties; the older report described its revenue mainly as biological products for non-therapeutic use.
20-F for FY2022, filed Apr 18, 2023 20-F for FY2025, filed Apr 17, 2026Bio Supplies. Net revenue from Bio Supplies primarily consists of revenue related to biological products for non-therapeutic use. The Bio…View ↗
Bio Supplies. Net revenue from Bio Supplies primarily consists of revenue related to biological products for non-therapeutic use and plasma…View ↗
Who Do They Compete With?
Competes with Takeda and CSL Group
20-F for FY2025, filed Apr 17, 2026We believe we are a leading plasma derivatives producer globally, ranking among the three largest producers in the industry in terms of…View ↗
Loading...
